Your session is about to expire
← Back to Search
Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg for Parkinson's Disease
Study Summary
This trial tests if a 15mg Tavapadon tablet is equivalent to taking 3x5mg tablets for Parkinson's disease.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history or symptoms of conditions like essential tremor or other Parkinson's-like disorders.You have experienced symptoms like seeing or hearing things that aren't there or having unusual thoughts or beliefs within the past year.You have a history of trying to harm yourself in the past.You are not allowed to participate if you have epilepsy or a history of seizures. However, if you only had febrile seizures in the past, you may be allowed to join with approval from a medical monitor.
- Group 1: Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg
- Group 2: Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this experiment accept volunteers of senior age?
"The study is seeking participants aged 45 or older and below the age of 80."
How many participants are there in this clinical investigation?
"Affirmative. According to records on clinicaltrials.gov, this medical experiment is seeking participants and was initially published in mid-December of 2022 before being revised a few days later. The goal is to recruit 24 people at 1 site for the trial."
How risk-free is Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg for patients?
"Considering the limited data available for Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg, it received a score of 1 in terms of safety. This is expected as this trial is at its initial phase and has yet to generate sufficient evidence regarding efficacy and security."
Are there any slots remaining for prospective participants in this investigation?
"Affirmative. According to information recorded on clinicaltrials.gov, this research is still looking for subjects to take part in it. Established on December 15th 2022, the trial's most recent update was made four days later and they are recruiting 24 individuals from a single location."
Who is eligible to join this research experiment?
"This clinical trial is recruiting 24 participants aged between 45 and 80 who have been diagnosed with Parkinson's disease. It is essential that these patients fulfill the following criteria: BMI from 17.5 to 38 kg/m^2, total body weight over 50kg (110lb) at screening, diagnosis in line with UK Brain Bank guidelines for PD, minimum L-Dopa dose of 300mg daily administered three times a day for two weeks prior to Day 1 Visit."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger